Hijacking solute carriers for proton-coupled drug transport.
about
How drugs get into cells: tested and testable predictions to help discriminate between transporter-mediated uptake and lipoidal bilayer diffusionMolecular insights into proton coupled peptide transport in the PTR family of oligopeptide transportersAlternating access mechanism in the POT family of oligopeptide transportersBarrier mechanisms in the Drosophila blood-brain barrierThe organic anion transporter (OAT) family: a systems biology perspectiveThe Concise Guide to PHARMACOLOGY 2013/14: transporters.Unconventional chemiosmotic coupling of NHA2, a mammalian Na+/H+ antiporter, to a plasma membrane H+ gradient.The human proton-coupled folate transporter: Biology and therapeutic applications to cancer.The kidney transcriptome and proteome defined by transcriptomics and antibody-based profilingInteraction of H+ with the extracellular and intracellular aspects of hMATE1.The SLC36 family of proton-coupled amino acid transporters and their potential role in drug transportContribution of tumoral and host solute carriers to clinical drug response.SLC15A2 genomic variation is associated with the extraordinary response of sorafenib treatment: whole-genome analysis in patients with hepatocellular carcinoma.Functional loss of the reduced folate carrier enhances the antitumor activities of novel antifolates with selective uptake by the proton-coupled folate transporter.The multidrug transporter MATE1 sequesters OCs within an intracellular compartment that has no influence on OC secretion in renal proximal tubulesDrug transporters on arachnoid barrier cells contribute to the blood-cerebrospinal fluid barrier.Role of the tryptophan residues in proton-coupled folate transporter (PCFT-SLC46A1) function.Towards a structural understanding of drug and peptide transport within the proton-dependent oligopeptide transporter (POT) family.Monocarboxylic acid transport.Dysregulated pH in Tumor Microenvironment Checkmates Cancer Therapy.Tenapanor administration and the activity of the H+ -coupled transporter PepT1 in healthy volunteers.The proton-coupled folate transporter (PCFT-SLC46A1) and the syndrome of systemic and cerebral folate deficiency of infancy: Hereditary folate malabsorption.Glycosylation affects the stability and subcellular distribution of human PAT1 protein.Harnessing Solute Carrier Transporters for Precision Oncology.Characterization of butyrate transport across the luminal membranes of equine large intestine.Amino acids suppress the expression of PAT1 on lysosomes via inducing the cleavage of a targeting signal.Kinetic Measurements of Di- and Tripeptide and Peptidomimetic Drug Transport in Different Kidney Regions Using the Fluorescent Membrane Potential-Sensitive Dye, DiS-C3-(3).Resculpting the binding pocket of APC superfamily LeuT-fold amino acid transporters.Concentrative transport of antifolates mediated by the proton-coupled folate transporter (PCFT, SLC46A1); augmentation by a HEPES buffer.Characterization of loxoprofen transport in Caco-2 cells: the involvement of a proton-dependent transport system in the intestinal transport of loxoprofen.
P2860
Q24273350-6E4FFED4-9E81-4711-840E-DA1B283BFB5CQ26830326-9C5921B9-63D6-4794-9848-894B4434DF22Q27679456-3FCDDD2A-5E56-4860-89DF-FAA72225C7A8Q28083620-E537AEAC-D2DA-4712-BC28-A88F9B3A5FECQ28085671-91B85F00-F820-4055-A0F1-9D733CD83798Q30486743-A7693ED4-ACEA-41C1-9253-B266300E9CC7Q34297529-80377BEA-3F9A-40B0-9ED2-E4A4208820D1Q34297931-59D6DC60-9917-413F-ADF3-C60EF5629B89Q34797374-621C7884-C9EB-4630-BDB2-D55886516306Q35216762-7BD4925A-D7E3-4A7A-A1EC-C53B9BED3C4EQ35636089-5A06890D-02D5-454D-B75A-7D70D7BB52B0Q35946876-F2F57CF9-E70E-4779-A76F-CFA357DA2E2DQ36140832-203E3927-0C2B-4145-93AA-3008EBC91325Q36294436-5097CE10-365E-4902-A127-E32FD85CA8B2Q36363344-C1BF5F72-5448-466B-B592-15293C39E9F6Q36717154-2809F210-1ED2-44D0-B940-C13A0AF7028BQ37139378-6DC99203-7CCB-4ADC-9188-08710B008E6EQ37936523-A1E88C1D-18FC-476D-B2C0-E25AD6B548E0Q38165142-3FAD8A20-061B-482F-9AB3-46451A25904CQ38181145-C7F11584-0C80-400B-8D07-1E1628697BE8Q38692100-DF59EC2E-5D8E-4592-8C23-D9C6B4AFAA37Q38963604-0324D765-5F58-43B4-B911-5B31192011D9Q39002062-12CA3BEB-8038-4595-95CE-E9D75F2F76F1Q39204754-DE23BF82-1A82-4A9D-B224-D3C91BAE1F58Q44628049-4C09085F-7FF0-44A0-BE45-9528D8207108Q45399530-00751068-7C51-47D6-910F-E037E3311CAFQ47681603-23999692-E97E-44EC-A614-F965EFF33BF6Q50067112-2F984C63-2B1F-403A-97CA-C30A08D8C32BQ50077775-982FAE75-9F37-451D-B9DE-EA80C666ACBAQ50559675-A8AE025D-1503-44EF-906C-E82C67574695
P2860
Hijacking solute carriers for proton-coupled drug transport.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Hijacking solute carriers for proton-coupled drug transport.
@en
Hijacking solute carriers for proton-coupled drug transport.
@nl
type
label
Hijacking solute carriers for proton-coupled drug transport.
@en
Hijacking solute carriers for proton-coupled drug transport.
@nl
prefLabel
Hijacking solute carriers for proton-coupled drug transport.
@en
Hijacking solute carriers for proton-coupled drug transport.
@nl
P2860
P1433
P1476
Hijacking solute carriers for proton-coupled drug transport
@en
P2093
David T Thwaites
P2860
P304
P356
10.1152/PHYSIOL.00027.2010
P577
2010-12-01T00:00:00Z